Trethera Strengthens Scientific Advisory Board With Rare Autoimmune Neurologic Disease Expert Dr. Benjamin Greenberg

Trethera Corporation, a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for cancer and autoimmune diseases, has announced the appointment of Dr. Benjamin Greenberg, MD, MHS, to its Scientific Advisory Board. Dr. Greenberg will play a key role in guiding the clinical development of Trethera’s lead asset, TRE-515, which is being developed for the treatment of demyelinating autoimmune diseases. These diseases involve damage to the myelin sheath, the protective covering surrounding nerve fibers. When this sheath is compromised, nerve impulses slow down or stop altogether, leading to serious neurological problems.

Dr. Greenberg is an internationally recognized neurologist with specialized expertise in rare autoimmune disorders of the central nervous system. He currently serves as Vice Chair of Clinical and Translational Research as well as Professor of Neurology and Pediatrics at UT Southwestern Medical Center. His medical training includes a degree from Baylor College of Medicine, an internal medicine internship at Rush–St. Luke’s Presbyterian Hospital, and a neurology residency at Johns Hopkins Hospital, where he also co-directed the Transverse Myelitis Center. Since joining UT Southwestern in 2009, Dr. Greenberg has founded several pioneering clinical programs, including the Transverse Myelitis and Neuromyelitis Optica Program and the Pediatric Demyelinating Disease Program.

Dr. Greenberg’s research and clinical work focus on demyelinating and inflammatory conditions such as acute disseminated encephalomyelitis (ADEM), optic neuritis, neuromyelitis optica spectrum disorder (NMOSD), and transverse myelitis. He has served as the principal investigator on major national collaborative studies that have led to the discovery of novel biomarkers and the development of biorepository protocols essential for precision diagnostics and tailored treatment strategies. His appointment strengthens Trethera’s commitment to advancing innovative therapies targeting autoimmune neurologic diseases.

Trethera’s lead drug candidate, TRE-515, currently holds FDA Orphan Drug designation for both optic neuritis and ADEM. This designation offers significant benefits, including expedited pathways to market approval, FDA guidance on clinical trial design, exemption from the \$4 million drug approval application fee, and seven years of marketing exclusivity. If approved for commercial use in ADEM, TRE-515 could also make Trethera eligible for a pediatric priority review voucher. TRE-515 is presently undergoing evaluation in a Phase 1 dose-escalation clinical trial focused on solid tumors.

Dr. Peter M. Clark Immunology Advisory Board Chairman of UCLA, said in a statement, “It’s fantastic to have Dr. Greenberg join our team. With his addition, we now have an exceptional and purpose-driven team at Trethera with the world’s foremost experts from Harvard, Stanford, and UT Southwestern to provide scientific answers as well as enroll patients in our forthcoming neuroimmunology Phase 1 clinical trials to transform patient care.”

Dr. Ken Schultz, Chairman and CEO of Trethera, stated, “I’m honored to have Dr. Greenberg join the Scientific Advisory Board and support the advancement of TRE-515 as a potential treatment for patients with rare demyelinating diseases. Safe and effective treatments for these neurologic conditions represent a significant unmet need, particularly in pediatric populations, where existing therapies often carry substantial side effects and deliver inconsistent results.”

ADEM is an autoimmune disease affecting approximately 15,000 patients annually in the United States, predominantly children aged six to eight. It often begins with fever and difficulty walking and can progress to severe outcomes such as loss of consciousness, coma, and even death. Optic neuritis, typically seen in adults, causes rapid vision loss in one or both eyes, with up to 25% of patients never fully regaining their eyesight. Each year, over 100,000 cases of optic neuritis are reported in the US, and the condition is closely linked to multiple sclerosis (MS). With Dr. Greenberg’s expertise supporting the clinical development of TRE-515, Trethera is poised to make significant advances in the treatment of these challenging autoimmune neurological conditions.